Stratagene Shares Up 5.9 Percent on New Dx Patent Award | GenomeWeb

NEW YORK, July 11 (GenomeWeb News) - Shares in Stratagene were up 5.9 percent, or $.51, at $9.14 in late-afternoon trading after the company said it won a US patent for its FullVelocity technology.


Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.